Impact of percentage of abnormal PC in TTP for patients at low risk. Patients with low MC (< 2 g/dL for MGUS and < 3 g/dL for SMM): (A) TTP was longer in MGUS patients with less than 95% aberrant PC (P < .002). (B) In SMM patients, the median TTP was 44 months versus not reached for patients with greater than or equal to 95% or less than 95% aberrant PC (P < .001). Patients without immunoparesis: (C) TTP was longer in MGUS patients with less than 95% aberrant PC (P = .02). (D) In SMM patients, the median TTP was 51 months versus not reached for patients with greater than or equal to 95% or less than 95% aberrant PC (P < .001).